Abbott Labs
This article was originally published in The Gray Sheet
Executive Summary
Michael Beatrice named VP-corporate and regulatory science, effective Nov. 1. Beatrice, who has 25 years of regulatory affairs experience having previously held positions in FDA's drugs and biologics centers, could prove valuable in upcoming discussions with the agency about recent compliance problems in the firm's diagnostics division (1"The Gray Sheet" Oct. 4, p. 16). Meanwhile, Abbott acquisition target Perclose has postponed to Nov. 19 its shareholders meeting to consider the combination, citing the uncertainty of the outcome of Abbott's discussions with FDA
You may also be interested in...
Abbott Facing FDA Consent Decree Over Alleged QSR Violations
Discussions between Abbott Labs and FDA over a proposed consent decree that could halt production of certain diagnostic products likely relate to quality system regulations (QSR) violations detected over a year ago at the firm's Abbott Park, Illinois facility.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.